1. Home
  2. DOMO vs TLSA Comparison

DOMO vs TLSA Comparison

Compare DOMO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Domo Inc. Class B

DOMO

Domo Inc. Class B

HOLD

Current Price

$3.42

Market Cap

132.7M

Sector

Technology

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.08

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOMO
TLSA
Founded
2010
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.7M
155.3M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
DOMO
TLSA
Price
$3.42
$1.08
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$10.28
N/A
AVG Volume (30 Days)
3.1M
199.2K
Earning Date
05-20-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
31.92
N/A
EPS
N/A
N/A
Revenue
$318,857,000.00
N/A
Revenue This Year
$3.41
N/A
Revenue Next Year
$4.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.57
N/A
52 Week Low
$1.84
$1.04
52 Week High
$18.49
$2.60

Technical Indicators

Market Signals
Indicator
DOMO
TLSA
Relative Strength Index (RSI) 53.75 39.65
Support Level $3.32 N/A
Resistance Level $3.99 $1.61
Average True Range (ATR) 0.29 0.11
MACD 0.04 -0.01
Stochastic Oscillator 64.81 2.44

Price Performance

Historical Comparison
DOMO
TLSA

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: